相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD38 identifies pre-activated CD8+T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer
Pin Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano et al.
CLINICAL CANCER RESEARCH (2021)
In vitro assessment of antitumor immune responses using tumor antigen proteins produced by transgenic silkworms
Kanae Yamada et al.
JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE (2021)
Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies
Carlos Hernandez et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
Mehdi R. Pirozyan et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy
Lisa K. Puntigam et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy
Adrian von Witzleben et al.
CELLS (2020)
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai et al.
BIOMARKER RESEARCH (2020)
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
Joshua R. Veatch et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy
Sara Valpione et al.
NATURE CANCER (2020)
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
Robert Haddad et al.
CANCER (2019)
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
James Clarke et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
Andre Kunert et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+T-lymphocytes in pancreatic cancer
Guoping Ding et al.
BMC CANCER (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Andrew B. Nixon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kyung Hwan Kim et al.
CLINICAL CANCER RESEARCH (2019)
Immunotherapy for head and neck cancer: Recent advances and future directions
John D. Cramer et al.
ORAL ONCOLOGY (2019)
The function and dysfunction of memory CD8+ T cells in tumor immunity
James L. Reading et al.
IMMUNOLOGICAL REVIEWS (2018)
Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report
Maysaloun Merhi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer
Nataly Manjarrez-Orduno et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
Akio Osa et al.
JCI INSIGHT (2018)
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Marta Luksza et al.
NATURE (2017)
Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients
Alice O. Kamphorst et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Unique phenotypes and clonal expansions of human CD4 effector memory T cells re-expressing CD45RA
Yuan Tian et al.
NATURE COMMUNICATIONS (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Central memory and effector memory T cell subsets: Function, generation, and maintenance
F Sallusto et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
分享论文
